Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07385430 · ClinicalTrials.gov registry record · Phase 1
Study of LGW16-03 To Identify Nerves
A Phase 1 study, sponsored by Eric R. Henderson.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT07385430 is a Phase 1 study that is actively recruiting participants, run by Eric R. Henderson. The registered enrollment target is 38 participants.
The verdict
NCT07385430, a Phase 1 study, is actively recruiting participants, sponsored by Eric R. Henderson.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The primary goal of this study is to determine the safety and tolerability of LGW16-03, a novel nerve-labeling fluorophore, in participants undergoing open-field orthopaedic surgery. Secondary goals include: 1) identifying the lowest dose without adverse events that provides peak florescence imaging contrast, and 2) characterizing the pharmacokinetics of LGW16-03. Participants will receive a one-time intravenous infusion of the investigational drug (LGW16-03) prior to their planned surgery. Participants' vitals will be closely monitored and will have blood samples taken at regular intervals. Fluorescence images of their major nerve will be taken during surgery. Participants will have one study follow-up visit approximately 30 days after their surgery.
Interventions
- DRUG LGW16-03
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07385430
The ClinicalTrials.gov registry entry for NCT07385430 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eric R. Henderson, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LGW16-03 is the first listed.
NCT07385430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07385430 about?
NCT07385430 is a clinical study titled "Study of LGW16-03 To Identify Nerves". The primary goal of this study is to determine the safety and tolerability of LGW16-03, a novel nerve-labeling fluorophore, in participants undergoing open-field orthopaedic surgery. Secondary goals include: 1) identifying the lowest dose without adverse events that provides peak florescence imaging...
What is the current status of trial NCT07385430?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2026-06-15. Estimated completion is 2027-08-01.
What interventions are being tested in trial NCT07385430?
The interventions under investigation include: LGW16-03 (DRUG).
Who is sponsoring clinical trial NCT07385430?
This trial is sponsored by Eric R. Henderson, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.